Clinical Trial Update: Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel plus cisplatin and gemcitabine in untreated metastatic pancreatic ductal adenocarcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: HonorHealth Research Institute | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-04-23